Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT03054792

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas: Feasibility Steps Toward Personalized Medicine.

Status
Enrolling By Invitation
Phase
Phase 1
Study type
Interventional
Enrollment
18 (estimated)
Sponsor
The Hospital for Sick Children · Academic / Other
Sex
All
Age
6 Years – 18 Years
Healthy volunteers
Not accepted

Summary

This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI and Magnetic Resonance Spectroscopy (MRS) with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (6-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBlood Oxygen Level Dependent [BOLD] MRIBOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
DIAGNOSTIC_TESTDiffusion-Weighted [DW] MRIDW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
DIAGNOSTIC_TESTMagnetic Resonance Spectroscopy [MRS]MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue

Timeline

Start date
2017-05-01
Primary completion
2025-06-01
Completion
2025-12-01
First posted
2017-02-16
Last updated
2024-12-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03054792. Inclusion in this directory is not an endorsement.